Hydroxyprogesterone oral - Lipocine

Drug Profile

Hydroxyprogesterone oral - Lipocine

Alternative Names: Hydroxyprogesterone caproate - Lipocine; LPCN-1107; Oral hydroxyprogesterone caproate - Lipocine

Latest Information Update: 05 Jul 2016

Price : $50

At a glance

  • Originator Lipocine
  • Class Hormones; Pregnenediones; Progesterone congeners; Small molecules
  • Mechanism of Action Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Preterm labour
  • New Molecular Entity No

Highest Development Phases

  • Phase I Preterm labour

Most Recent Events

  • 10 Mar 2016 Lipocine has patent protection for LPOCN 1107 in USA and South Africa (Lipocine, Form 10-K, March 2016)
  • 16 Feb 2016 Positive pharmacokinetic and adverse events data from a phase I trial in Preterm labour released by Lipocine
  • 28 Sep 2015 Lipocine initiates a phase I pharmacokinetic trial for Preterm labour in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top